MASP ISOFORMS AS INHIBITORS OF COMPLEMENT ACTIVATION
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to novel ficolin-associated polypeptides, and polypeptides derived from these ficolin-associated polypeptides for the use in the treatment of conditions associated with inflammation, apoptosis, autoimmunity, coagulation, thrombotic or coagulopathic related diseases, as well as the use as biomarkers. The present invention further relates to anti-bodies recognising such novel ficolin-associated polypeptides, and polypeptides derived thereof, nucleic acid molecules encoding such polypeptides, vectors and host cells used in the production of the polypeptides.
-
Citations
64 Claims
- 1. An isolated ficolin-associated polypeptide.
-
2. (canceled)
-
4-6. -6. (canceled)
-
10. (canceled)
-
12-15. -15. (canceled)
-
16. A polypeptide comprising the amino acid sequence of SEQ ID NO:
- 4 or variants or immunologic fragment thereof.
-
17-20. -20. (canceled)
-
23. (canceled)
-
26-28. -28. (canceled)
-
34-44. -44. (canceled)
-
46-53. -53. (canceled)
-
55. A method for diagnosing a disorder associated with aberrant expression of a ficolin-associated polypeptide, comprising obtaining a biological sample from a patient and measuring the expression in said biological sample of said ficolin-associated polypeptide, wherein increased or decreased expression of said ficolin-associated polypeptide in said biological sample compared to a control indicates that said patient suffers from a disorder associated with aberrant expression of a ficolin-associated polypeptide.
-
56-63. -63. (canceled)
Specification